Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free AMIX Stock Alerts

Trading of Autonomix Medical was halted at 03:44 PM EST due to "LULD Pause".

Autonomix Medical (AMIX) Competitors

Autonomix Medical logo
$19.50 +15.85 (+434.25%)
Closing price 04:00 PM Eastern
Extended Trading
$14.70 -4.80 (-24.63%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

AMIX vs. VVOS, NDRA, PAVM, CODX, and SONX

Should you buy Autonomix Medical stock or one of its competitors? MarketBeat compares Autonomix Medical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Autonomix Medical include Vivos Therapeutics (VVOS), ENDRA Life Sciences (NDRA), PAVmed (PAVM), Co-Diagnostics (CODX), and Sonendo (SONX).

How does Autonomix Medical compare to Vivos Therapeutics?

Autonomix Medical (NASDAQ:AMIX) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

In the previous week, Autonomix Medical had 16 more articles in the media than Vivos Therapeutics. MarketBeat recorded 16 mentions for Autonomix Medical and 0 mentions for Vivos Therapeutics. Autonomix Medical's average media sentiment score of 0.35 beat Vivos Therapeutics' score of 0.00 indicating that Autonomix Medical is being referred to more favorably in the media.

Company Overall Sentiment
Autonomix Medical Neutral
Vivos Therapeutics Neutral

Autonomix Medical has a beta of -1.17, suggesting that its stock price is 217% less volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.22, suggesting that its stock price is 522% more volatile than the broader market.

Autonomix Medical has a net margin of 0.00% compared to Vivos Therapeutics' net margin of -127.70%. Autonomix Medical's return on equity of -239.36% beat Vivos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Autonomix MedicalN/A -239.36% -192.46%
Vivos Therapeutics -127.70%-2,325.64%-98.12%

Autonomix Medical presently has a consensus price target of $42.00, suggesting a potential upside of 115.38%. Vivos Therapeutics has a consensus price target of $2.80, suggesting a potential upside of 505.80%. Given Vivos Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Vivos Therapeutics is more favorable than Autonomix Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Autonomix Medical
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Vivos Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

10.8% of Autonomix Medical shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 6.2% of Autonomix Medical shares are owned by company insiders. Comparatively, 2.1% of Vivos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Autonomix Medical has higher earnings, but lower revenue than Vivos Therapeutics. Autonomix Medical is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Autonomix MedicalN/AN/A-$16.72M-$74.58N/A
Vivos Therapeutics$17.44M0.37-$21.17M-$2.14N/A

Summary

Vivos Therapeutics beats Autonomix Medical on 9 of the 15 factors compared between the two stocks.

How does Autonomix Medical compare to ENDRA Life Sciences?

Autonomix Medical (NASDAQ:AMIX) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

10.8% of Autonomix Medical shares are held by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are held by institutional investors. 6.2% of Autonomix Medical shares are held by company insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Autonomix Medical had 16 more articles in the media than ENDRA Life Sciences. MarketBeat recorded 16 mentions for Autonomix Medical and 0 mentions for ENDRA Life Sciences. ENDRA Life Sciences' average media sentiment score of 2.00 beat Autonomix Medical's score of 0.35 indicating that ENDRA Life Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
Autonomix Medical Neutral
ENDRA Life Sciences Very Positive

Autonomix Medical currently has a consensus target price of $42.00, indicating a potential upside of 115.38%. ENDRA Life Sciences has a consensus target price of $25.00, indicating a potential upside of 492.42%. Given ENDRA Life Sciences' higher possible upside, analysts plainly believe ENDRA Life Sciences is more favorable than Autonomix Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Autonomix Medical
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
ENDRA Life Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Autonomix Medical has a beta of -1.17, suggesting that its stock price is 217% less volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.05, suggesting that its stock price is 105% less volatile than the broader market.

Autonomix Medical's return on equity of -239.36% beat ENDRA Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Autonomix MedicalN/A -239.36% -192.46%
ENDRA Life Sciences N/A -433.64%-204.58%

ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Autonomix Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Autonomix MedicalN/AN/A-$16.72M-$74.58N/A
ENDRA Life SciencesN/AN/A-$7.03M-$8.15N/A

Summary

ENDRA Life Sciences beats Autonomix Medical on 6 of the 11 factors compared between the two stocks.

How does Autonomix Medical compare to PAVmed?

PAVmed (NASDAQ:PAVM) and Autonomix Medical (NASDAQ:AMIX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

19.9% of PAVmed shares are owned by institutional investors. Comparatively, 10.8% of Autonomix Medical shares are owned by institutional investors. 13.4% of PAVmed shares are owned by company insiders. Comparatively, 6.2% of Autonomix Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

PAVmed has higher revenue and earnings than Autonomix Medical. Autonomix Medical is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PAVmed$70K72.00$400K-$37.40N/A
Autonomix MedicalN/AN/A-$16.72M-$74.58N/A

In the previous week, Autonomix Medical had 12 more articles in the media than PAVmed. MarketBeat recorded 16 mentions for Autonomix Medical and 4 mentions for PAVmed. Autonomix Medical's average media sentiment score of 0.35 beat PAVmed's score of 0.15 indicating that Autonomix Medical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PAVmed
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Autonomix Medical
0 Very Positive mention(s)
0 Positive mention(s)
16 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

PAVmed has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market. Comparatively, Autonomix Medical has a beta of -1.17, indicating that its stock price is 217% less volatile than the broader market.

PAVmed currently has a consensus price target of $56.00, suggesting a potential upside of 1,011.11%. Autonomix Medical has a consensus price target of $42.00, suggesting a potential upside of 115.38%. Given PAVmed's higher probable upside, equities research analysts clearly believe PAVmed is more favorable than Autonomix Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PAVmed
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Autonomix Medical
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Autonomix Medical has a net margin of 0.00% compared to PAVmed's net margin of -21,914.12%. PAVmed's return on equity of -146.19% beat Autonomix Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
PAVmed-21,914.12% -146.19% -18.39%
Autonomix Medical N/A -239.36%-192.46%

Summary

PAVmed beats Autonomix Medical on 10 of the 13 factors compared between the two stocks.

How does Autonomix Medical compare to Co-Diagnostics?

Co-Diagnostics (NASDAQ:CODX) and Autonomix Medical (NASDAQ:AMIX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Autonomix Medical has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,760.63%. Co-Diagnostics' return on equity of -164.92% beat Autonomix Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Co-Diagnostics-6,760.63% -164.92% -141.15%
Autonomix Medical N/A -239.36%-192.46%

Co-Diagnostics has a beta of 2.87, indicating that its stock price is 187% more volatile than the broader market. Comparatively, Autonomix Medical has a beta of -1.17, indicating that its stock price is 217% less volatile than the broader market.

15.0% of Co-Diagnostics shares are held by institutional investors. Comparatively, 10.8% of Autonomix Medical shares are held by institutional investors. 2.3% of Co-Diagnostics shares are held by insiders. Comparatively, 6.2% of Autonomix Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Autonomix Medical has lower revenue, but higher earnings than Co-Diagnostics. Autonomix Medical is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Co-Diagnostics$620K9.01-$46.90M-$15.77N/A
Autonomix MedicalN/AN/A-$16.72M-$74.58N/A

Co-Diagnostics currently has a consensus target price of $67.50, indicating a potential upside of 4,358.39%. Autonomix Medical has a consensus target price of $42.00, indicating a potential upside of 115.38%. Given Co-Diagnostics' higher possible upside, research analysts plainly believe Co-Diagnostics is more favorable than Autonomix Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Co-Diagnostics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Autonomix Medical
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Autonomix Medical had 14 more articles in the media than Co-Diagnostics. MarketBeat recorded 16 mentions for Autonomix Medical and 2 mentions for Co-Diagnostics. Autonomix Medical's average media sentiment score of 0.35 beat Co-Diagnostics' score of 0.29 indicating that Autonomix Medical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Co-Diagnostics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Autonomix Medical
0 Very Positive mention(s)
0 Positive mention(s)
16 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Co-Diagnostics beats Autonomix Medical on 8 of the 13 factors compared between the two stocks.

How does Autonomix Medical compare to Sonendo?

Sonendo (NYSE:SONX) and Autonomix Medical (NASDAQ:AMIX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

Autonomix Medical has a net margin of 0.00% compared to Sonendo's net margin of -92.74%. Sonendo's return on equity of -184.01% beat Autonomix Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Sonendo-92.74% -184.01% -68.60%
Autonomix Medical N/A -239.36%-192.46%

Autonomix Medical has a consensus price target of $42.00, indicating a potential upside of 115.38%. Given Autonomix Medical's stronger consensus rating and higher probable upside, analysts clearly believe Autonomix Medical is more favorable than Sonendo.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sonendo
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Autonomix Medical
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Autonomix Medical has lower revenue, but higher earnings than Sonendo. Autonomix Medical is trading at a lower price-to-earnings ratio than Sonendo, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sonendo$44.40M0.11-$60.92M-$71.12N/A
Autonomix MedicalN/AN/A-$16.72M-$74.58N/A

In the previous week, Autonomix Medical had 16 more articles in the media than Sonendo. MarketBeat recorded 16 mentions for Autonomix Medical and 0 mentions for Sonendo. Autonomix Medical's average media sentiment score of 0.35 beat Sonendo's score of 0.00 indicating that Autonomix Medical is being referred to more favorably in the news media.

Company Overall Sentiment
Sonendo Neutral
Autonomix Medical Neutral

28.7% of Sonendo shares are held by institutional investors. Comparatively, 10.8% of Autonomix Medical shares are held by institutional investors. 7.9% of Sonendo shares are held by company insiders. Comparatively, 6.2% of Autonomix Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Sonendo has a beta of 1.86, indicating that its share price is 86% more volatile than the broader market. Comparatively, Autonomix Medical has a beta of -1.17, indicating that its share price is 217% less volatile than the broader market.

Summary

Sonendo beats Autonomix Medical on 8 of the 15 factors compared between the two stocks.

Get Autonomix Medical News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMIX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AMIX vs. The Competition

Export
MetricAutonomix MedicalHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.98M$5.78B$6.84B$12.76B
Dividend YieldN/A1.78%2.59%10.01%
P/E Ratio-0.2623.45279.1425.53
Price / SalesN/A59.00591.0494.27
Price / CashN/A32.6072.1149.39
Price / Book1.806.1312.956.11
Net Income-$16.72M$150.91M$3.48B$347.58M
7 Day Performance609.09%6.44%2.59%3.17%
1 Month Performance203.27%1.07%-2.79%-2.06%
1 Year Performance-30.70%9.90%64.29%21.19%

Autonomix Medical Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMIX
Autonomix Medical
2.3295 of 5 stars		$19.50
+434.2%		$42.00
+115.4%		-87.5%$1.98MN/AN/A1
VVOS
Vivos Therapeutics
1.5365 of 5 stars		$0.41
-1.5%		$2.80
+576.5%		-91.9%$5.84M$17.44MN/A160
NDRA
ENDRA Life Sciences
3.1741 of 5 stars		$4.45
-0.2%		$25.00
+461.8%		-14.0%$5.66MN/AN/A20
PAVM
PAVmed
3.3214 of 5 stars		$5.10
-5.2%		$56.00
+998.0%		-65.1%$5.36M$70KN/A90
CODX
Co-Diagnostics
1.7932 of 5 stars		$1.51
+7.1%		$67.50
+4,370.2%		-80.1%$5.20M$620KN/A100

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AMIX) was last updated on 8/4/2026 by MarketBeat.com Staff.
From Our Partners
"Second Wave” Hitting Iran Soon? Wall Street Issues Warning
Analysts at Goldman Sachs and Morgan Stanley are warning that a quiet domestic threat - unrelated to overseas ...
TradeSmith | Sponsoredtc pixel
He bet half his $9 billion on ONE stock
One of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund ...
Stansberry Research | Sponsoredtc pixel
Did you forget to grab this?
Most beginners stay stuck on the sidelines for years because no one shows them the simple steps between being ...
Profits Run | Sponsoredtc pixel
Central banks bought 710 tonnes - this fund pays monthly
Gold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...
Investors Alley | Sponsoredtc pixel
1 Stock to Own by July 31st
A scheduled announcement on July 31st could reshuffle the stock market's winners and losers - and one lesser-k...
Chaikin Analytics | Sponsoredtc pixel
70% of the Fortune 100 depend on this mystery AI stock
Seventy percent of the Fortune 100 already rely on one company's AI cybersecurity platform, which combines mor...
The Oxford Club | Sponsoredtc pixel
Free Stock Pick: The Company First in Line for America’s New Super Fuel
The U.S. Army and Department of Energy are launching Project Janus - a high-priority initiative ordered by Pre...
Banyan Hill Publishing | Sponsoredtc pixel
Now that SpaceX is public, buy this ticker (no, not SpaceX or Tesla)
The SpaceX IPO wasn't the big trade - according to Larry Benedict, founder of The Opportunistic Trader, it was...
Brownstone Research | Sponsoredtc pixel